Cargando…
Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report
This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that th...
Autores principales: | Ryou, Jae Hyun, Han, Doug Hyun, Lee, Reeree, Kim, Sun Mi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329106/ https://www.ncbi.nlm.nih.gov/pubmed/35879044 http://dx.doi.org/10.9758/cpn.2022.20.3.581 |
Ejemplares similares
-
Tardive Dyskinesia: Treatment with Aripiprazole
por: Kang, Na-Ri, et al.
Publicado: (2011) -
Aripiprazole in Tardive Dyskinesia: Is it a Safe Choice?
por: Doval, Nimisha, et al.
Publicado: (2017) -
Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019) -
A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution
por: Heitzmann, Edwige, et al.
Publicado: (2016) -
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans
por: Herz, Damian M., et al.
Publicado: (2015)